metformin has been researched along with Neurocysticercosis in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Neurocysticercosis: Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Racemose neurocysticercosis is an aggressive infection caused by the aberrant expansion of the cyst form of Taenia solium within the subarachnoid spaces of the human brain and spinal cord, resulting in the displacement of the surrounding host tissue and chronic inflammation." | 5.72 | Proliferative cells in racemose neurocysticercosis have an active MAPK signalling pathway and respond to metformin treatment. ( Garcia, HH; Nash, TE; Orrego, MA; Vasquez, CM; Verastegui, MR, 2022) |
| "Racemose neurocysticercosis is an aggressive infection caused by the aberrant expansion of the cyst form of Taenia solium within the subarachnoid spaces of the human brain and spinal cord, resulting in the displacement of the surrounding host tissue and chronic inflammation." | 1.72 | Proliferative cells in racemose neurocysticercosis have an active MAPK signalling pathway and respond to metformin treatment. ( Garcia, HH; Nash, TE; Orrego, MA; Vasquez, CM; Verastegui, MR, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orrego, MA | 1 |
| Verastegui, MR | 1 |
| Vasquez, CM | 1 |
| Garcia, HH | 1 |
| Nash, TE | 1 |
1 other study available for metformin and Neurocysticercosis
| Article | Year |
|---|---|
Proliferative cells in racemose neurocysticercosis have an active MAPK signalling pathway and respond to metformin treatment.
Topics: Animals; Cysts; Humans; Metformin; Mice; Mitogen-Activated Protein Kinases; Neurocysticercosis; Taen | 2022 |